|
Allergy Therapeutics PLC shares declined on Monday, despite the firm saying it expects to report increased revenue for its first half. The stock was down 10% at 10.89 pence on Monday morning in London. Allergy Therapeutics anticipates revenue of £36.3 million for the six months ended December 31, up 7% or 3% at constant currency from £34.0 million the year before. This was despite ‘the ongoing transition away from unregistered products under Germany’s TAV programme’, the company said, adding that the increase reflects strong growth in its existing German registered product portfolio. The Sussex, England-based biotechnology firm added that it expects overall group sales for the year ending June 30 to exceed those achieved in financial 2025. It noted that commercialisation of its Grassmuno immunotherapy started this month, and said it expects sales momentum to accelerate further in the second half. Allergy Therapeutics reported a cash balance of £10.1 million at December 31, down from £12.8 million on June 30. Also, it said it has access to a total of £70 million in uncommitted funding. ‘We enter 2026 with strong momentum across all aspects of our business,’ Chief Executive Officer Manuel Llobet commented. ‘The first half of the year saw growth driven by improved operational execution and the restoration of reliability across our supply chain...Together, the significant achievements of 2025 and our ongoing development programs position us well to execute our strategy and build sustainable value for the group and shareholders.’ The board remains confident in delivering revenue growth for financial 2026, Allergy Therapeutics said. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
